人肉瘤细胞系中侧群细胞的内唾液酸蛋白表达
Endosialin expression in side populations in human sarcoma cell lines.
作者信息
Rouleau Cecile, Sancho Jose, Campos-Rivera Juanita, Teicher Beverly A
机构信息
Genzyme Corporation, Framingham, MA 01701, USA.
出版信息
Oncol Lett. 2012 Feb;3(2):325-329. doi: 10.3892/ol.2011.478. Epub 2011 Nov 14.
Abstract
The Hoechst 33342 exclusion side population (SP) assay is a validated method used to identify cells with stem cell-like properties. When isolated from tumors, SP cells have been shown to have high malignant potential. SPs have been found in both carcinomas and sarcomas. The molecular profile of sarcoma SP is poorly understood. The purpose of the present study was to determine whether endosialin is a suitable therapeutic target for sarcomas. Six cell lines (HT-1080 fibrosarcoma, SJSA-1 and HOS osteosarcoma, A-673 and SK-ES-1 Ewing sarcoma) were used for the SP analysis. Flow cytometry was used to count and examine the cells. Results showed for the first time that endosialin (CD248), which was previously identified as a sarcoma marker, is expressed in sarcoma SP cells. This observation supports the hypothesis that endosialin is a promising therapeutic target for sarcomas.
摘要
Hoechst 33342 排斥侧群（SP）分析是一种用于鉴定具有干细胞样特性细胞的有效方法。当从肿瘤中分离出来时，SP细胞已被证明具有高恶性潜能。在癌和肉瘤中均发现了SP细胞。肉瘤SP细胞的分子特征了解甚少。本研究的目的是确定内涎蛋白是否是肉瘤的合适治疗靶点。使用六种细胞系（HT-1080纤维肉瘤、SJSA-1和HOS骨肉瘤、A-673和SK-ES-1尤因肉瘤）进行SP分析。采用流式细胞术对细胞进行计数和检测。结果首次表明，先前被鉴定为肉瘤标志物的内涎蛋白（CD248）在肉瘤SP细胞中表达。这一观察结果支持了内涎蛋白是肉瘤有前景的治疗靶点这一假说。
相似文献
1
Endosialin expression in side populations in human sarcoma cell lines.人肉瘤细胞系中侧群细胞的内唾液酸蛋白表达
Oncol Lett. 2012 Feb;3(2):325-329. doi: 10.3892/ol.2011.478. Epub 2011 Nov 14.
2
Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies.抗内皮唾液酸蛋白抗体-药物偶联物：在肉瘤及其他恶性肿瘤中的潜力
Mol Cancer Ther. 2015 Sep;14(9):2081-9. doi: 10.1158/1535-7163.MCT-15-0312. Epub 2015 Jul 16.
3
Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma.人实体瘤中内唾液酸蛋白的表达及治疗靶点潜力：肉瘤与癌的比较
Clin Cancer Res. 2008 Nov 15;14(22):7223-36. doi: 10.1158/1078-0432.CCR-08-0499.
4
Endosialin: a novel malignant cell therapeutic target for neuroblastoma.内皮细胞唾液酸糖蛋白受体：神经母细胞瘤的一种新的恶性细胞治疗靶点。
Int J Oncol. 2011 Oct;39(4):841-51. doi: 10.3892/ijo.2011.1091. Epub 2011 Jun 20.
5
Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling.Endosialin 在高级别和晚期肉瘤中表达：来自临床标本和临床前模型的证据。
Int J Oncol. 2011 Jul;39(1):73-89. doi: 10.3892/ijo.2011.1020. Epub 2011 Apr 29.
6
Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells.内涎蛋白在软组织肉瘤中的表达作为未分化间充质细胞的潜在标志物。
Br J Cancer. 2016 Aug 9;115(4):473-9. doi: 10.1038/bjc.2016.214. Epub 2016 Jul 19.
7
Endosialin/CD248 may be a potential therapeutic target to prevent the invasion and metastasis in osteosarcoma.内唾液酸蛋白/CD248可能是预防骨肉瘤侵袭和转移的潜在治疗靶点。
Oncol Lett. 2022 Feb;23(2):42. doi: 10.3892/ol.2021.13160. Epub 2021 Dec 6.
8
Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II.生长激素释放激素拮抗剂在体外和体内对人MNNG/HOS骨肉瘤细胞系和SK-ES-1尤因肉瘤细胞系增殖的抑制作用：对胰岛素样生长因子II的影响
Cancer. 2002 Oct 15;95(8):1735-45. doi: 10.1002/cncr.10865.
9
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma.一种靶向内涎蛋白的新型抗体药物偶联物的产生：在肉瘤中产生强大且持久的抗肿瘤反应。
Oncotarget. 2017 Jul 22;8(36):60368-60377. doi: 10.18632/oncotarget.19499. eCollection 2017 Sep 1.
10
Endosialin and Associated Protein Expression in Soft Tissue Sarcomas: A Potential Target for Anti-Endosialin Therapeutic Strategies.软组织肉瘤中内源性唾液酸酶及相关蛋白表达：抗内源性唾液酸酶治疗策略的潜在靶点
Sarcoma. 2016;2016:5213628. doi: 10.1155/2016/5213628. Epub 2016 Jan 27.
引用本文的文献
1
Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches.内皮细胞唾液酸糖蛋白受体在癌症中的表达模式、作用机制及治疗方法。
Theranostics. 2024 Jan 1;14(1):379-391. doi: 10.7150/thno.89495. eCollection 2024.
2
Chemoresistance-Related Stem Cell Signaling in Osteosarcoma and Its Plausible Contribution to Poor Therapeutic Response: A Discussion That Still Matters.骨肉瘤中与化疗耐药相关的干细胞信号及其对治疗反应不良的可能贡献：一个仍有意义的讨论。
Int J Mol Sci. 2022 Sep 27;23(19):11416. doi: 10.3390/ijms231911416.
3
Endosialin defines human stem Leydig cells with regenerative potential.内唾液酸糖蛋白(endosialin)可鉴定具有再生潜能的人源睾丸间质干细胞。
Hum Reprod. 2020 Oct 1;35(10):2197-2212. doi: 10.1093/humrep/deaa174.
4
C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation.C 型凝集素结构域家族 14 蛋白在血管生物学、癌症和炎症中的作用。
FEBS J. 2019 Sep;286(17):3299-3332. doi: 10.1111/febs.14985. Epub 2019 Jul 29.
5
CD248: A therapeutic target in cancer and fibrotic diseases.CD248：癌症和纤维化疾病的治疗靶点。
Oncotarget. 2019 Jan 29;10(9):993-1009. doi: 10.18632/oncotarget.26590.
6
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma.一种靶向内涎蛋白的新型抗体药物偶联物的产生：在肉瘤中产生强大且持久的抗肿瘤反应。
Oncotarget. 2017 Jul 22;8(36):60368-60377. doi: 10.18632/oncotarget.19499. eCollection 2017 Sep 1.
7
Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells.内涎蛋白在软组织肉瘤中的表达作为未分化间充质细胞的潜在标志物。
Br J Cancer. 2016 Aug 9;115(4):473-9. doi: 10.1038/bjc.2016.214. Epub 2016 Jul 19.
8
Endosialin and Associated Protein Expression in Soft Tissue Sarcomas: A Potential Target for Anti-Endosialin Therapeutic Strategies.软组织肉瘤中内源性唾液酸酶及相关蛋白表达：抗内源性唾液酸酶治疗策略的潜在靶点
Sarcoma. 2016;2016:5213628. doi: 10.1155/2016/5213628. Epub 2016 Jan 27.
9
Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications.用于体内TEM-1/内涎蛋白PET应用的89Zr-奥妥珠单抗的研发。
Oncotarget. 2016 Mar 15;7(11):13082-92. doi: 10.18632/oncotarget.7552.
10
TEM1 expression in cancer-associated fibroblasts is correlated with a poor prognosis in patients with gastric cancer.癌相关成纤维细胞中TEM1的表达与胃癌患者的不良预后相关。
Cancer Med. 2015 Nov;4(11):1667-78. doi: 10.1002/cam4.515. Epub 2015 Sep 4.
本文引用的文献
1
Endosialin: from vascular target to biomarker for human sarcomas.内皮糖蛋白：从血管靶点到人类肉瘤的生物标志物。
Biomark Med. 2009 Oct;3(5):589-604. doi: 10.2217/bmm.09.54.
2
Circulating tumor cells: a window into cancer biology and metastasis.循环肿瘤细胞：癌症生物学和转移的窗口。
Curr Opin Genet Dev. 2010 Feb;20(1):96-9. doi: 10.1016/j.gde.2009.12.002. Epub 2010 Jan 12.
3
Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis.癌症干细胞作为预防肿瘤进展和转移的新治疗靶点。
Front Biosci (Elite Ed). 2010 Jan 1;2(2):602-13. doi: 10.2741/e117.
4
Detection and characterization of side population in Ewing's sarcoma SK-ES-1 cells in vitro.体外检测和鉴定尤因肉瘤 SK-ES-1 细胞中的侧群。
Biochem Biophys Res Commun. 2010 Jan 1;391(1):1062-6. doi: 10.1016/j.bbrc.2009.12.020. Epub 2009 Dec 10.
5
Tumor heterogeneity: causes and consequences.肿瘤异质性：成因与后果
Biochim Biophys Acta. 2010 Jan;1805(1):105-17. doi: 10.1016/j.bbcan.2009.11.002. Epub 2009 Nov 18.
6
Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.强效、口服有效的小分子 MDM2-p53 相互作用抑制剂。
J Med Chem. 2009 Dec 24;52(24):7970-3. doi: 10.1021/jm901400z.
7
Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas.侧群细胞具有骨肉瘤中癌干细胞/肿瘤起始细胞的特征。
Br J Cancer. 2009 Oct 20;101(8):1425-32. doi: 10.1038/sj.bjc.6605330. Epub 2009 Sep 29.
8
Mechanisms of chemotherapeutic drug resistance in cancer therapy--a quick review.癌症治疗中化疗耐药的机制——简要综述
Taiwan J Obstet Gynecol. 2009 Sep;48(3):239-44. doi: 10.1016/S1028-4559(09)60296-5.
9
Functional in vivo optical imaging of tumor angiogenesis, growth, and metastasis prevented by administration of anti-human VEGF antibody in xenograft model of human fibrosarcoma HT1080 cells.在人纤维肉瘤HT1080细胞异种移植模型中，抗人VEGF抗体给药可预防肿瘤血管生成、生长和转移的功能性体内光学成像。
Cancer Sci. 2009 Nov;100(11):2085-92. doi: 10.1111/j.1349-7006.2009.01305.x. Epub 2009 Aug 3.
10
Side population and cancer stem cells: therapeutic implications.侧群细胞和癌症干细胞：治疗意义。
Cancer Lett. 2010 Feb 1;288(1):1-9. doi: 10.1016/j.canlet.2009.05.020. Epub 2009 Jun 11.
Zotero 插件